Ingalox® eucalyptus (Tincture) Instructions for Use
Marketing Authorization Holder
Kirov Pharmaceutical Factory, JSC (Russia)
ATC Code
R02AA20 (Other antiseptics)
Active Substance
Eucalypti folium (DAB German Pharmacopoeia)
Dosage Form
| Ingalox® eucalyptus | Tincture (200 g/1 L): 25 mL, 40 mL, or 100 mL bottle, 25 mL or 40 mL dropper bottle. |
Dosage Form, Packaging, and Composition
Tincture as a clear greenish-brown liquid with a characteristic odor.
| 1 bottle | |
| Tincture of Eucalyptus viminalis leaves (200 g of plant material per 1 L of tincture) | 100 ml |
Extraction solvent ethanol 70%.
25 ml – orange glass bottles (1) – cardboard packs.
40 ml – orange glass bottles (1) – cardboard packs.
100 ml – orange glass bottles (1) – cardboard packs.
25 ml – orange glass dropper bottles (1) – cardboard packs.
40 ml – orange glass dropper bottles (1) – cardboard packs.
Clinical-Pharmacological Group
Herbal preparation with antimicrobial and anti-inflammatory action
Pharmacotherapeutic Group
Antiseptic of plant origin
Pharmacological Action
Herbal remedy. Aqueous and alcoholic extracts from eucalyptus leaves exhibit bactericidal, antiviral, fungicidal, antiprotozoal, and anti-inflammatory effects. The degree of their expression depends on the content of essential oil (0.3-4.5%).
The activity of the main component of the essential oil, cineole (65-85%), is potentiated by pinenes, myrtenol, and tannins (up to 6%). When taken orally and in inhalations, eucalyptus preparations cause expectorant, mucolytic, and bronchodilator effects, and when applied to the skin, an astringent, anti-exudative, antipruritic, anesthetic, and in higher concentrations, a local irritant effect. Eucalyptus leaf infusion, due to the essential oil and a small amount of bitters, increases the secretion of the digestive glands and improves digestion. When used in the form of a tincture, a sedative effect is manifested, due to the aldehyde of isovaleric acid.
Chlorophyllipt, containing a mixture of chlorophylls from eucalyptus leaves, has antimicrobial, especially antistaphylococcal, activity and stimulates regeneration processes. Components of the essential oil, together with organic acids, tannins, and trace elements manganese, zinc, and selenium, increase tissue resistance to hypoxia of various origins.
Indications
As part of combination therapy for acute and chronic infectious and inflammatory diseases of various locations: rhinitis, stomatitis, gingivitis, laryngitis, bronchitis, pneumonia, hyposecretory gastritis, enterocolitis, dysbiosis, cholecystitis, pyelonephritis, vaginitis, colpitis, cervical erosion, burns, dermatitis, radiculitis, neuritis, myositis, trophic ulcers, neurosis, mild form of insomnia, osteochondrosis.
ICD codes
| ICD-10 code | Indication |
| F48.0 | Neurasthenia |
| F51.0 | Nonorganic insomnia |
| J00 | Acute nasopharyngitis (common cold) |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J31.2 | Chronic pharyngitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| K05 | Gingivitis and periodontal diseases |
| K12 | Stomatitis and related lesions |
| K29 | Gastritis and duodenitis |
| K52.9 | Noninfective gastroenteritis and colitis, unspecified |
| K63.8 | Other specified diseases of intestine |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| L30.9 | Dermatitis, unspecified |
| L98.4 | Chronic skin ulcer, not elsewhere classified |
| M42 | Spinal osteochondrosis |
| M54.1 | Radiculopathy |
| M54.3 | Sciatica |
| M54.4 | Lumbago with sciatica |
| M60 | Myositis |
| M79.2 | Neuralgia and neuritis, unspecified |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N76 | Other inflammatory diseases of vagina and vulva |
| N86 | Erosion and ectropion of cervix |
| T30 | Burns and corrosions of unspecified body region |
| ICD-11 code | Indication |
| 6A8Z | Affective disorders, unspecified |
| 7A00 | Chronic insomnia |
| 7A01 | Acute insomnia |
| 7A0Z | Insomnia disorders, unspecified |
| 8B93.Z | Radiculopathy, unspecified |
| 8E4A.1 | Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system |
| CA00 | Acute nasopharyngitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09.0 | Chronic rhinitis |
| CA09.2 | Chronic pharyngitis |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| DA01.Z | Diseases of the oral mucosa, unspecified |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DA90.0 | Syndromic diarrhea |
| DA92.1 | Pneumatosis intestinalis of the small intestine |
| DA98.Z | Polyps of small intestine, unspecified |
| DB31.1 | Pneumatosis of the colon |
| DB36.Z | Certain infections of the colon, unspecified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DE2Z | Diseases of the digestive system, unspecified |
| EA40 | Tropical phagedenic ulcer |
| EA85.2Z | Hand dermatitis, unspecified |
| EA85.3 | Foot dermatitis |
| EA89 | Generalized eczematous dermatitis of unspecified type |
| EA8Z | Dermatitis or eczema, unspecified |
| EF60 | Ischemic ulceration of the skin |
| EM0Z | Unspecified skin disorder |
| FA85.Z | Defects of vertebral end-plates, unspecified |
| FB30 | Infectious myositis |
| FB32 | Other specified disorders of muscle |
| FB3Z | Disorder of muscle, unspecified |
| FB56 | Specified soft tissue diseases, not elsewhere classified |
| FB56.0 | Granuloma of soft tissue due to foreign body, not elsewhere classified |
| GA00 | Vulvitis |
| GA02.Z | Unspecified vaginitis |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| GA15.1 | Erosion or ectropion of cervix |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| ME60.2 | Ulcerative skin lesion of unspecified nature |
| ME84.20 | Lumbago with sciatica |
| ME84.3 | Sciatica |
| NE11 | Burn of unspecified body region |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally, externally, topically, by inhalation, or intracavitary.
For oral administration, dilute 15-30 drops in 1/2 glass of water. Take 3-4 times daily.
For gargling and mouthwash, use 10-15 drops diluted in one glass of warm water. Apply 4-5 times daily.
For inhalation, add 10-15 drops to an inhaler or 200 mL of hot water. Inhale the vapors for 5-10 minutes, 1-2 times daily.
For topical application on skin and wounds, use undiluted or diluted tincture for irrigation, compresses, or tampons. Apply to affected areas 2-4 times daily.
For intracavitary use in gynecology, dilute 1 teaspoon in 200-400 mL of water or 0.9% sodium chloride solution. Use for douching or tamponade.
For neuralgia, radiculitis, or myositis, rub the undiluted tincture into the affected area 2-3 times daily.
Adjust the dose, frequency, and duration individually based on indication and patient response.
Before initiating treatment, perform a sensitivity test by administering 10 drops orally in water and monitor for allergic reactions for 6-8 hours.
Adverse Reactions
Possible allergic reactions to components of the essential oil and chlorophyllipt; when taken orally in high doses – nausea, vomiting, diarrhea, muscle spasms; with frequent and/or prolonged inhalation use – dryness of the mucous membranes of the respiratory tract.
Contraindications
Hypersensitivity to components of the essential oil and chlorophyllipt; atrophy of the mucous membranes of the upper respiratory tract.
Use in Pregnancy and Lactation
The use of eucalyptus leaf preparations containing ethyl alcohol is contraindicated during pregnancy and breastfeeding.
Pediatric Use
The use of eucalyptus leaf preparations containing ethyl alcohol is contraindicated in children and adolescents under 18 years of age.
Special Precautions
Use with caution in cases of increased secretion of the digestive glands.
Avoid contact of eucalyptus preparations (especially tincture, eucalyptus oil, chlorophyllipt) with the eyes.
Before starting treatment, it is necessary to check the patient’s sensitivity to the plant. For this, the patient is given a tablespoon of infusion, 10 drops of tincture, or 25 drops of a 1% alcohol solution of chlorophyllipt in 1 tablespoon of water. If no allergic reactions occur within 6-8 hours, a course of treatment can be prescribed. A negative attitude of the patient towards the smell of eucalyptus may indicate intolerance.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Mildronate capsules 500mg, 90pcs
Nootropil pills 800mg, 30pcs 